ArticleScientific reports2016
Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.BMC infectious diseases · 2023Pooled it
- Article
- Epidemiological patterns, risk factors, and prevention gaps of surgical site infections in operating rooms: a hospital-based surveillance study.Frontiers in public health · 2026Article
- Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Preneutropenic Fever in Patients With Hematological Malignancies: A Novel Target for Antimicrobial Stewardship.Open forum infectious diseases · 2024Article
- Using whole genome sequencing to characterizeAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated byFrontiers in cellular and infection microbiology · 2023Article
- Outcomes ofEuropean journal of hospital pharmacy : science and practice · 2022Article
- Clostridioides difficile Diarrhea: An Emerging Problem in a South Indian Tertiary Care Hospital.Journal of laboratory physicians · 2021Article
- Healthcare associatedThe Libyan journal of medicine · 2020Article
- Article
- Exploratory Evaluation of Bezlotoxumab on Outcomes Associated WithOpen forum infectious diseases · 2020Article
- High Prevalence of Genetically RelatedFrontiers in microbiology · 2020Article
- Treatment of RecurrentCase reports in infectious diseases · 2020Article
- Determining the risk factors associated with the development ofBlood research · 2019Article
- Leptin receptor q223r polymorphism influences neutrophil mobilization after Clostridium difficile infection.Mucosal immunology · 2018Article
- Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.Anaerobe · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence on risk factors for Clostridium difficile infection (CDI) in hemato-oncologic patients is conflicting. We studied risk factors for CDI in a large, well-characterized cohort of hemato-oncological patients. 144 hemato-oncological patients were identified in this retrospective, single center study with a microbiologically confirmed CDI-associated diarrhea. Patients were compared with 144 age and sex matched hemato-oncologic patients with CDI negative diarrhea. Risk factors such as prior antimicrobial therapy, type of disease, chemotherapy and survival were evaluated. CDI-positive patients received more frequently any antimicrobial agent and antimicrobial combination therapy than CDI-negative patients (79% vs. 67%; OR = 2.26, p = 0.038 and OR = 2.62, p = 0.003, respectively). CDI positive patients were treated more frequently with antimicrobial agents active against C. difficile than CDI negative ones (25% vs. 13%; OR = 2.2, p = 0.039). The interval between last chemotherapy and onset of diarrhea was significantly shorter in patients without CDI (median, 17 days vs 36 days; p < 0.001). Our study demonstrates that chemotherapy is not a significant risk factor for CDI but for early onset CDI negative diarrhea. The predominant modifiable risk factor for CDI is in hemato-oncological patients antimicrobial treatment. These findings should be taken into account in the daily clinical practice to avoid CDI associated complications and excess health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.